Amylyx Pharmaceuticals, Inc. (AMLX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 1.6800 |
| Open | 1.7000 |
| Bid | 1.6000 x 200 |
| Ask | 1.6500 x 400 |
| Day's range | 1.6200 - 1.7000 |
| 52-week range | 1.6200 - 25.4800 |
| Volume | |
| Avg. volume | 1,870,107 |
| Market cap | 111.53M |
| Beta (5Y monthly) | -0.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
Amylyx Pharmaceuticals Reports Q1 2024 Financial Results
Significant Revenue Growth Amidst Strategic Shifts and Clinical Developments
- Insider Monkey
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2024 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2024 Earnings Call Transcript May 9, 2024 Amylyx Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.75071 EPS, expectations were $0.24. AMLX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. My name […]
- Zacks
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates
Amylyx Pharmaceuticals (AMLX) delivered earnings and revenue surprises of -291.67% and 21.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
© 2024 Yahoo. All rights reserved.